3rd ALS Drug Development Summit 2024 Hyatt Regency Boston, Boston

Identify Transformative ALS Targets, Seek Translational Biomarkers and Propel More Clinical Approvals

Following monumental progress in 2023, the ALS treatment landscape is surging with novel innovation to navigate the complex, multifactorial nature of motor neuron degeneration and develop more truly transformative drugs for sporadic and familial ALS.

Capitalizing on rapid pipeline progress and emerging industry investment, the 3rd Annual ALS Drug Development Summit returns to Boston, providing a comprehensive breakdown of the latest motor neuron models, biomarker strategies, approval insights, and novel approaches to target the likes of TDP-43, STMN2, and PIKfyve. Engage in forward-thinking discussions and gain fresh perspectives on the most meaningful endpoints and trial design considerations for people living with ALS.

This May, join your industry colleagues across discovery, preclinical, clinical, regulatory, and commercial from the likes of Biogen, Amylyx, AbbVie, NeuroSense, Mitsubishi, Sanofi, Takeda, Novartis, and more.